Revolutionizing Oncology: Radiomedix Secures $40 Million in Series A Financing for Groundbreaking Targeted Alpha Therapy and Diagnostic Radiopharmaceuticals
Revolutionizing Oncology: Radiomedix Secures $40 Million in Series A Financing for Groundbreaking Targeted Alpha Therapy and Diagnostic Radiopharmaceuticals HOUSTON and BURLINGTON, Ontario, Oct. 07, 2022 (GLOBE NEWSWIRE) — RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced an agreement with an entity related to Portland Investment Counsel Inc. (“Portland”) involving an equity investment of…